文献速递头颈外科

HPV阴性口咽癌原发治疗生存结局:国家癌症数据库分析

Human Papillomavirus-Negative Oropharyngeal Cancer Survival Outcomes Based on Primary Treatment: National Cancer Database Analysis.
PubMed 文献 · Otolaryngol Head Neck Surg · 2021-09-21

该回顾性队列研究基于美国国家癌症数据库2010—2014年2635例HPV阴性口咽鳞癌患者,比较原发手术与放疗±化疗的总体生存。按分期分组后,早期N0-1及T1-2N2-3患者手术组5年OS显著更优;T3-4N0-1与T3-4N2-3两组手术与放化疗差异无统计学意义。

要点

  • T1-2N0-1患者原发手术5年OS显著优于单纯放疗和放化疗。
  • T1-2N2-3患者手术加辅助治疗5年OS显著优于放化疗。
  • T3-4N0-1及T3-4N2-3患者手术与放化疗生存差异无统计学意义。

核心结论

  • 原发手术可能在许多HPV阴性口咽鳞癌病例中提供更好的生存结局。
  • 上述数据可用于权衡治疗选择,并可能为细化HPV阴性疾病的治疗算法提供依据。

研究设计与样本

  • 回顾性观察性队列研究。
  • 数据来源为美国国家癌症数据库。
  • 纳入2010—2014年接受手术或放疗±化疗的2635例HPV阴性口咽鳞癌患者。
  • 对所有变量进行单因素分析并纳入多因素模型。
  • 主要结局为总体生存(OS)。

临床怎么用

  • 对HPV阴性口咽鳞癌患者,尤其T1-2N0-1和T1-2N2-3期,可优先考虑原发手术以改善生存。
  • T3-4N0-1和T3-4N2-3期患者手术与放化疗生存无显著差异,治疗选择应个体化。

局限性

  • 回顾性观察性研究设计,存在选择偏倚可能。
  • 数据来源于国家癌症数据库,可能存在未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare survival outcomes between primary surgery and primary radiation therapy (RT) in patients with human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma (OPSCC). STUDY DESIGN: A retrospective observational cohort study. SETTING: National Cancer Database. METHODS: A National Cancer Database review was conducted of 2635 patients with HPV-negative OPSCC who underwent surgery or RT ± chemotherapy between 2010 and 2014. Univariate analysis was performed on all variables and entered into a multivariate model. The main outcome was overall survival (OS). RESULTS: A total of 2635 patients with HPV-negative OPSCC were organized into 4 groups based on cancer staging. In group 1 (T1-2 N0-1; n = 774), up-front surgery had significantly better 5-year OS (76.2%) than RT (56.8%; adjusted hazard ratio [aHR], 1.76; P = .009; 95% CI, 1.15-2.69) and chemoradiation therapy (CRT; 69.5%; aHR, 1.56; P = .019; 95% CI, 1.08-2.26). In group 2 (T3-4 N0-1; n = 327), no significant difference existed between surgery and CRT (5-year OS, 51.3% vs 52.4%; aHR, 0.96; P = .88; 95% CI, 0.54-1.69). In group 3a (T1-2 N2-3; n = 807), surgery with adjuvant treatment showed significantly better 5-year OS than CRT (78.6% vs 68.8%; aHR, 1.51; P = .027; 95% CI, 1.05-2.18). In group 3b (T3-4 N2-3; n = 737), surgery with adjuvant treatment was not statistically associated with better 5-year OS as compared with CRT (61.0% vs 43.7%; aHR, 1.53; P = .06; 95% CI, 0.98-2.39). CONCLUSION: Primary surgery may provide improved survival outcomes in many cases of HPV-negative OPSCCs. These data should be used in weighing treatment options and may serve as a basis to better delineate treatment algorithms for HPV-negative disease.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Shama M, Al-Qurayshi Z, Dahl M, et al. Human Papillomavirus-Negative Oropharyngeal Cancer Survival Outcomes Based on Primary Treatment: National Cancer Database Analysis. Otolaryngol Head Neck Surg. 2021. PMID: 34546828. doi:10.1177/01945998211047169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。